Canadian Biotech Co. Appoints Elite Regulatory Expert for Chile Expansion

1. MindBio Therapeutics Corp. is a billboard sponsor of Streetwise Reports and pays SWR a monthly sponsorship fee between US$3,000 and US$6,000. 
2. As of the date of this article, officers, contractors, shareholders, and/or employees of Streetwise Reports LLC (including members of their household) own securities of MindBio Therapeutics Corp.
3. Cori Fisher wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee. 
4. This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company. 
5. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

1. Disclosure for the quote from the Stewart Thomson article published on [Date]

1. For the quoted article April 1, 2026, MindBio Therapeutics Corp. has paid Street Smart, an affiliate of Streetwise Reports, US$3,500.
2. Author Certification and Compensation: Stewart Thomson was retained and compensated as an independent contractor by Street Smart for writing this article. Mr. Thomson is a retired Canadian financial advisor who has passed the Canadian Securities Course as well as additional technical analysis courses that were mandated by his former employer and approved by Ontario regulatory bodies. For the past 15 years, he has been editing and writing numerous financial newsletters that have a strong focus on charts.  The recommendations and opinions expressed in this content reflect the personal, independent, and objective views of the author regarding any and all of the companies discussed. No part of the compensation received by the author was, is, or will be directly or indirectly tied to the specific recommendations or views expressed.

For additional disclosures, please click here.

2. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

MindBio Therapeutics Corp. (MBIO:CSE; MBQIF:OTCQB; WF6:Frankfurt) announced the appointment of Chilean drug policy specialist Felipe Leyton as head of commercialization in its South American mining industry market. On February 24, 2026, OTC Markets called this move a ". . . significant inflection point as MindBio transitions from advanced development to commercial field deployment.  

Felipe Leyton has served as the head of Chile's National Alcohol Prevention Unit, as well as the head of other national prevention programs. He was the lead of technical operation and implementation of Chile's Zero Tolerance alcohol law and contributed to the creation of Chile's national roadside drug testing program in 2019. Working with MindBio won't be Leyton's first foray into the mining industry, as he is currently a partner at TC Consulting. There, his job is to advise Chilean mining operators and governments on drug and alcohol prevention strategies, regulatory compliance, workplace health promotion, and industrial safety culture transformation.

In his role with MindBio, Leyton is anticipated to develop and finalize mining-specific testing protocols with the company, refine the AI prediction models, help strengthen the kiosk's ability to detect abuse of multiple illicit substances, develop licensing frameworks with working mines, and oversee deployment into said mines.

Justin Hanka, CEO of MindBio, said of Leyton's employment, "Mr. Leyton brings exceptional credibility, regulatory authority, and direct access to the mining industry. He helped design and implement Chile's Zero Tolerance alcohol framework at a national level, and he now leads the commercialization in a world-first AI voice-based impairment detection platform for mining. This marks a transition from technology development to structured commercial deployment. We believe this positions MindBio at the forefront of next-generation industrial safety solutions and Voice initiated health diagnostic technologies."

The Company's Development

MindBio Therapeutics is a Canadian biotech company levering AI technology to detect impairment from drugs or alcohol through voice analysis. The company is developing software that could help reduce intoxication-related accidents in both corporate and personal settings. Its proprietary technology analyzes over 140 vocal markers, sifting through parameters like spectral entropy, jitter, and shimmer, and speech rate variability.

The company hopes to help create ". . . a world where voice-based biomarkers are a standard component of healthcare — enabling continuous, passive health monitoring that catches problems early and improves outcomes for everyone, everywhere."

MindBio's personal-use app, Booze AI, is described as "the world's first voice-activated AI-powered blood alcohol test" and is deployed via smartphone. The app is now live and available to the public. The company aims to promote social responsibility, personal awareness, and harm prevention among individual users.

In a move toward corporate usage, MindBio has focused its attention on commercial applications and is currently building Edge-AI kiosks to implement non-invasive intoxication screenings at large mining sites.

In a conversation with Streetwise Reports, MindBio CEO, Justin Hanka, discussed the expense of screening mining employees for intoxication: "In Chile, there are about 220,000 mining workers going on and off site every day. If you had to test 10% of them every day — that's 20,000 workers. If you were charged just US$1 for every test, that's US$20,000 a day, seven days a week . . . and that's just one part of the world, and two mining sites."

MindBio aims to provide the benefits of screening in zero-tolerance industries without the usual pitfalls of being invasive, time-consuming, and seemingly targeting. "The core reason why a company wants to do this is that 25% of incidents are caused by alcohol and drug intoxication, directly or indirectly," Hanka said to Streetwise Reports.

Currently, MindBio is developing inroads into the mining, aviation, construction, and law enforcement industries.

Addiction in the Mining Industry

In a recent market presentation, MindBio asserted that detecting drug and alcohol intoxication at scale can prevent unnecessary harm. The company discussed how physiological decline can put lives at risk, citing the dangers of impaired driving and a 10-20x increase in suicide risk while heavily intoxicated. MindBio also said that 40-50% of suicides involve alcohol, while the global alcohol harm cost sits at around US$1.6 trillion.

According to the American Addiction Centers, many factors contribute to addiction and abuse risk, like parental monitoring, peer pressure, socioeconomic status, type of substance, stress, drug availability, and occupation. They classified the mining industry as "particularly conducive to substance abuse," due to job stress, physical demand, and injuries from prolonged work.

Outside the addiction sphere, biotech, in general, has shown exponential growth recently. "The global biotechnology market size was estimated at US$1.55 trillion in 2023 and is projected to reach US$3.88 trillion by 2030, growing at a CAGR of 13.96% from 2024 to 2030," said Grandview Research. And AI is carving out its own place in biotech. In September 2025, Market and Market Analysis considered the AI detector market as "undergoing rapid expansion, with estimates projecting a substantial market value surge from approximately US$0.58 billion in 2025 to US$2.06 billion in 2030."

Industry Professionals Watching Rollout

¹"AI stocks are bottoming, and flashing buy signals . . . and MindBio leads the pack," wrote Stewart Thomson in a contributed technical analyst opinion for Streetwise Reports on April 1, 2026. Thomson argued that AI can be critical to creating a safer mining industry, saying, "MindBio's AI decodes these acoustic signatures to reveal physiological states and does it with unprecedented precision." Thomson gave MindBio a 'Strong Speculative Buy' rating and a long-term price target of CA$6.00. 

On February 3, 2026, The Canadian Mining Journal reported that, "Studies in Chile reveal that alcohol consumption among mining workers exceeds 75%, with over 40% classified as problem drinkers." The article went on to say, "A single preventable incident can cost a mining company hundreds of millions in lost production, union boycotts, and insurance and medical expenses."

Knowlton Thomas, for Techcouver, wrote on January 26, 2026, that ". . . Leveraging more than 50 million data points from drug and alcohol clinical trials and proprietary algorithms across over 100 acoustic parameters, MindBio is now commercializing its technology." 

"AI stocks are bottoming, and flashing buy signals . . . and MindBio leads the pack."

Deployment Planned Mid-2026

In its investor presentation, MindBio states it aims to deploy its Edge AI voice drug and alcohol detection kiosks in June of 2026 in order to test at scale in zero-tolerance industries. The company is already partnering with mines in South America and is in talks with other industries.

While enterprise and telehealth capacities are in development right now, the company's announced future plans include disease prediction and health optimization.

Ownership & Share Structure²

MindBio Therapeutics Corp. has a market cap of CA$7.9 million, with 7.28 million shares outstanding. The company's 52-week trading range is CA$0.50-CA$8.00.

Management and Insiders own approximately 5.80% of MindBio Therapeutics shares, with Retail investors holding the remaining 94.20%.